Drug Trial Radar · NCT00689338
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Last checked: Nov 20, 2026Latest source record: May 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
216
Actual
Start
Jul 2008
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.
Conditions
- Invasive Candidiasis
Interventions
AnidulafunginDrug
Anidulafungin Intravenous Administration
FluconazoleDrug
Oral Administration of Fluconazole
VoriconazoleDrug
Oral Administration of Voriconazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Global Treatment Response Success at End of TreatmentTime frame: End of Treatment (Day 14 to Day 56)
Locations
61 sites in 19 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Vienna, Austria
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Ghent, Belgium
Pfizer Investigational Site
Leuven, Belgium
Pfizer Investigational Site
Liège, Belgium
Pfizer Investigational Site
Yvoir, Belgium
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Brno, Czechia
Pfizer Investigational Site
Ostrava, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Koebenhavn OE, Denmark
Pfizer Investigational Site
Odense C, Denmark
Pfizer Investigational Site
Villejuif, France
Pfizer Investigational Site
Amiens, France, France
Pfizer Investigational Site
Bordeaux, France, France
Pfizer Investigational Site
Clichy, France, France
Pfizer Investigational Site
Lyon, France, France
Pfizer Investigational Site
Marseille, France, France
Pfizer Investigational Site
Montpellier, France, France
Pfizer Investigational Site
Paris, France, France
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
Freiburg im Breisgau, Germany
Pfizer Investigational Site
Wuppertal, Germany
Pfizer Investigational Site
Kifissia, Athens, Greece
Pfizer Investigational Site
Haidari, Attica, Greece
Pfizer Investigational Site
Budapest, Hungary
Pfizer Investigational Site
Budapest, Hungary
Pfizer Investigational Site
Pisa, Italy
Pfizer Investigational Site
Roma, Italy
Pfizer Investigational Site
Roma, Italy
Pfizer Investigational Site
Torino, Italy
Pfizer Investigational Site
Udine, Italy
Pfizer Investigational Site
Ede, Netherlands
Pfizer Investigational Site
Rotterdam, Netherlands
Pfizer Investigational Site
Krakow, Poland
Pfizer Investigational Site
Lodz, Poland
Pfizer Investigational Site
Coimbra, Portugal
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.